Benign Prostatic Hyperplasia Prostate Treatment Market Size & Share, by Treatment Type (Drug, Surgical Treatment); Therapeutic Class {BPH Devices (Transurethral RF Thermal Therapy, Suture Base Implant), BPH Drugs (Alpha Blocker, Muscarinic Receptor Antagonist, 5-Alpha Reductase Inhibitors)}; Distribution Channel (Pharmacies, Online, Institutional Sales) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

Request Free Sample Copy

Report ID: 4218
Published Date: Feb 22, 2023
Report Format: PDF, PPT

Buy Now

Companies Dominating the Benign Prostatic Hyperplasia Prostate Treatment Landscape

Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Cardinal Health Inc.
NxThera, Inc.
Veru, Inc.
Teleflex Incorporated
Eli Lily & Company
Sanofi S.A.
GSK plc
Mylan N.V.
AbbVie Inc.

Browse Key Market Insights with Data Illustration:

Benign Prostatic Hyperplasia Prostate Treatment Market Size Forecasts 2035

In the News

Teleflex Incorporated announced the results of research studies regarding the efficacy and safety of UroLift systems. The system is developed for men diagnosed with benign prostatic hyperplasia (BPH) and median lobe obstruction.
Veru Inc. announced that it has received approval by the United States Food and Drug Administration (FDA) for its finasteride and tadalafil capsules, known as ENTADFI, which is used to treat urinary tract symptoms caused as a result of an enlarged prostate, commonly known as BPH.

Frequently Asked Questions (FAQ)

Higher prevalence of benign prostatic hyperplasia (BPH), developing medical technology across the globe, increasing healthcare expenditure per capita, and spiking cases of urinary tract infection are estimated to majorly boost the market growth.

The market is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023-2035.

Government initiatives regarding the sales and consumption of medicines, and lack of awareness of the disease in developing countries are estimated to challenge the market growth.

The market in North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Cardinal Health Inc., NxThera, Inc., Veru, Inc., Teleflex Incorporated, Eli Lily & Company, Sanofi S.A., GSK plc, Mylan N.V., AbbVie Inc., Pfizer Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue-generating capacity as well as the new products being launched into the market by the company.

The market is segmented by therapeutic class, distribution channel, treatment type, and by region

The drug treatment segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Companies Dominating the Benign Prostatic Hyperplasia Prostate Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the benign prostatic hyperplasia (BPH) prostate treatment market?

What would be the CAGR of benign prostatic hyperplasia (BPH) prostate treatment market over the forecast period?

What are the challenges affecting the benign prostatic hyperplasia (BPH) prostate treatment market growth?

Which region will provide more business opportunities for growth of benign prostatic hyperplasia (BPH) prostate treatment market in future?

Who are the major players dominating the benign prostatic hyperplasia (BPH) prostate treatment market?

How are the company profiles selected?

Which segment captures the largest market size in the distribution channel in the benign prostatic hyperplasia (BPH) prostate treatment market?

What are the segments in the benign prostatic hyperplasia (BPH) prostate treatment market?